Clinical Trials Directory

Trials / Completed

CompletedNCT05056584

The Role of the Kidneys and Liver in the Elimination of Glucagon

The Role of the Kidneys and Liver in the Elimination of Glucagon An Evaluation of the Metabolic Clearance Rate of Glucagon in Patients With End-stage Renal Disease and Patients With Liver Cirrhosis

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
48 (actual)
Sponsor
University Hospital, Gentofte, Copenhagen · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Accepted

Summary

The study aims to evaluate the kinetics and effect of glucagon in patients with chronic kidney disease and liver cirrhosis and matched healthy subjects, respectively.

Detailed description

In the present project the investigators wish to identify whether the effect, elimination and degradation of glucagon differ between healthy control subjects and patients with Chronic Kidney Disease (CKD) and liver cirrhosis, respectively. By performing glucagon infusions on healthy control subjects and matched subjects with either limited renal and hepatic function, the contribution of both organs to the metabolic clearance rate (MCR) of glucagon can be tested. A primed infusion of stable isotopic labelled tracers will allow the researchers to investigate the effects of the glucagon infusion on the glucose, lipid and amino acid metabolism. The quantification of the MCR of glucagon will be accompanied by a range of pharmacodynamic measures in order to substantiate whether a potentially altered glucagon MCR inflicts pharmacodynamic changes of glucagon, which could contribute to the pathophysiology of CKD and liver cirrhosis.

Conditions

Interventions

TypeNameDescription
BIOLOGICALGlucagon infusionOne hour glucagon-clamp followed by one hour of blood sampling
BIOLOGICALPrimed tracer infusionInfusion of primed isotopically labelled glucose, amino acids and lipids. From 2 hours prior to glucagon infusion and throughout the test day,

Timeline

Start date
2020-08-01
Primary completion
2023-03-28
Completion
2023-03-28
First posted
2021-09-24
Last updated
2023-05-12

Locations

1 site across 1 country: Denmark

Source: ClinicalTrials.gov record NCT05056584. Inclusion in this directory is not an endorsement.